suxamethonium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
quaternary ammonium compounds	2489	306-40-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: suxamethonium chloride succinylcholine suxamethonium dicholine succinate succinic acid dicholine diester succinocholine succinoylcholine succinylbischoline succinylcholine chloride	A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for. Molecular weight: 290.40 Formula: C14H30N2O4 CLOGP: -6.87 LIPINSKI: 0 HAC: 6 HDO: 0 TPSA: 52.60 ALOGS: -5.68 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

suxamethonium chloride
succinylcholine
suxamethonium
dicholine succinate
succinic acid dicholine diester
succinocholine
succinoylcholine
succinylbischoline
succinylcholine chloride

A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.

Molecular weight: 290.40
Formula: C14H30N2O4
CLOGP: -6.87
LIPINSKI: 0
HAC: 6
HDO: 0
TPSA: 52.60
ALOGS: -5.68
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Aug. 20, 1952	FDA	SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	580.78	41.29	162	4405	23471	63460984
Hyperthermia malignant	194.50	41.29	36	4531	798	63483657
Cardiac arrest	192.34	41.29	105	4462	92440	63392015
Hypotension	189.20	41.29	156	4411	272448	63212007
Exposure during pregnancy	177.21	41.29	120	4447	155427	63329028
Diabetes insipidus	158.62	41.29	37	4530	2588	63481867
Anaphylactic reaction	131.65	41.29	73	4494	66027	63418428
Renal ischaemia	126.53	41.29	24	4543	609	63483846
PCO2 increased	121.73	41.29	26	4541	1213	63483242
Bronchospasm	121.57	41.29	46	4521	17234	63467221
Maternal exposure during pregnancy	108.47	41.29	104	4463	219958	63264497
PO2 increased	101.03	41.29	21	4546	858	63483597
Foetal death	98.61	41.29	35	4532	10945	63473510
Blood pH decreased	97.76	41.29	25	4542	2562	63481893
Neuromuscular block prolonged	92.50	41.29	18	4549	524	63483931
Oxygen saturation abnormal	90.07	41.29	25	4542	3504	63480951
Blood bicarbonate decreased	89.83	41.29	24	4543	2917	63481538
Ventricular tachycardia	88.03	41.29	38	4529	19941	63464514
Rhabdomyolysis	85.95	41.29	48	4519	43903	63440552
Left ventricular dysfunction	84.61	41.29	32	4535	11956	63472499
Apnoea	81.36	41.29	28	4539	7994	63476461
Delayed recovery from anaesthesia	80.42	41.29	17	4550	754	63483701
Foetal exposure during pregnancy	79.59	41.29	41	4526	31921	63452534
Bradycardia	72.57	41.29	52	4515	73175	63411280
Premature baby	70.79	41.29	33	4534	20702	63463753
Seizure	67.68	41.29	64	4503	132570	63351885
Status epilepticus	67.18	41.29	29	4538	15204	63469251
Electroencephalogram abnormal	62.54	41.29	19	4548	3653	63480802
Hyperkalaemia	59.52	41.29	41	4526	54162	63430293
Maternal exposure during delivery	59.15	41.29	15	4552	1485	63482970
Premature delivery	58.98	41.29	33	4534	30248	63454207
Tracheal deviation	57.57	41.29	10	4557	152	63484303
Phrenic nerve paralysis	55.67	41.29	10	4557	186	63484269
Renal impairment	55.60	41.29	48	4519	88307	63396148
Blood magnesium decreased	54.53	41.29	24	4543	13174	63471281
Drug interaction	52.47	41.29	73	4494	229058	63255397
Patent ductus arteriosus	51.65	41.29	17	4550	4233	63480222
Anaesthetic complication	50.54	41.29	14	4553	1946	63482509
Clonus	50.20	41.29	17	4550	4619	63479836
Kounis syndrome	47.58	41.29	13	4554	1717	63482738
Encephalopathy	46.65	41.29	31	4536	38589	63445866
Premature labour	42.97	41.29	20	4547	12484	63471971
Pulseless electrical activity	42.18	41.29	17	4550	7504	63476951
Pseudocholinesterase deficiency	42.07	41.29	7	4560	81	63484374
Myoclonic epilepsy	41.94	41.29	11	4556	1243	63483212

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	393.48	34.12	80	3424	2097	34951330
Anaphylactic shock	300.07	34.12	96	3408	15845	34937582
Cardiac arrest	166.45	34.12	109	3395	96050	34857377
Serotonin syndrome	139.81	34.12	58	3446	19875	34933552
Anaphylactic reaction	118.87	34.12	60	3444	32241	34921186
Neuromuscular block prolonged	82.11	34.12	17	3487	484	34952943
Electrocardiogram ST segment elevation	80.01	34.12	27	3477	5211	34948216
Rhabdomyolysis	79.79	34.12	61	3443	68102	34885325
Hypotension	79.71	34.12	104	3400	221545	34731882
Procedural hypotension	66.35	34.12	16	3488	920	34952507
Anaesthetic complication	63.50	34.12	16	3488	1104	34952323
Drug interaction	60.30	34.12	92	3412	225854	34727573
Seizure like phenomena	59.02	34.12	14	3490	750	34952677
Bradycardia	58.07	34.12	53	3451	75365	34878062
Pseudocholinesterase deficiency	55.94	34.12	8	3496	19	34953408
Respiratory acidosis	54.09	34.12	20	3484	5030	34948397
Bronchospasm	51.67	34.12	24	3480	10707	34942720
Metabolic acidosis	50.84	34.12	39	3465	43641	34909786
Apnoea	48.71	34.12	20	3484	6644	34946783
Muscle rigidity	45.96	34.12	22	3482	10496	34942931
Ventricular tachycardia	45.41	34.12	30	3474	26549	34926878
Stress cardiomyopathy	41.09	34.12	13	3491	2046	34951381
Tachycardia	40.39	34.12	46	3458	84726	34868701
Pseudomonal sepsis	37.81	34.12	14	3490	3533	34949894
Neuromuscular blockade	37.61	34.12	8	3496	260	34953167
Blood creatine phosphokinase increased	35.40	34.12	32	3472	44825	34908602
Hypoxia	35.28	34.12	35	3469	55060	34898367
Pulseless electrical activity	34.31	34.12	16	3488	7195	34946232

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	861.14	30.19	259	7566	35737	79700826
Hyperthermia malignant	545.72	30.19	110	7715	2807	79733756
Cardiac arrest	328.47	30.19	206	7619	171890	79564673
Anaphylactic reaction	246.50	30.19	133	7692	83610	79652953
Hypotension	240.21	30.19	253	7572	440064	79296499
Neuromuscular block prolonged	169.83	30.19	35	7790	995	79735568
Bronchospasm	164.35	30.19	69	7756	24790	79711773
Exposure during pregnancy	146.13	30.19	102	7723	101030	79635533
Rhabdomyolysis	144.33	30.19	102	7723	103029	79633534
Ventricular tachycardia	127.11	30.19	68	7757	41867	79694696
Bradycardia	125.78	30.19	105	7720	135452	79601111
Serotonin syndrome	125.32	30.19	69	7756	44958	79691605
Diabetes insipidus	121.84	30.19	37	7788	5200	79731363
PCO2 increased	118.53	30.19	29	7796	1811	79734752
Maternal exposure during pregnancy	110.87	30.19	98	7727	136440	79600123
Anaesthetic complication	110.50	30.19	30	7795	2829	79733734
Renal ischaemia	109.91	30.19	25	7800	1137	79735426
Apnoea	103.26	30.19	40	7785	11664	79724899
Pseudocholinesterase deficiency	101.19	30.19	17	7808	149	79736414
Foetal death	98.58	30.19	35	7790	8009	79728554
Delayed recovery from anaesthesia	95.84	30.19	24	7801	1649	79734914
Drug interaction	95.05	30.19	156	7669	415027	79321536
Blood pH decreased	87.42	30.19	28	7797	4683	79731880
PO2 increased	87.09	30.19	22	7803	1566	79734997
Oxygen saturation abnormal	79.99	30.19	26	7799	4556	79732007
Electrocardiogram ST segment elevation	78.72	30.19	30	7795	8367	79728196
Left ventricular dysfunction	71.88	30.19	36	7789	19325	79717238
Diarrhoea	70.55	30.19	4	7821	880485	78856078
Blood bicarbonate decreased	69.01	30.19	24	7801	5167	79731396
Procedural hypotension	67.89	30.19	19	7806	2004	79734559
Tachycardia	67.35	30.19	85	7740	177683	79558880
Pulseless electrical activity	66.70	30.19	31	7794	14129	79722434
Neuromuscular blockade	63.14	30.19	14	7811	566	79735997
Hyperkalaemia	58.81	30.19	64	7761	114334	79622229
Fatigue	57.38	30.19	11	7814	929716	78806847
Hypoxia	57.02	30.19	60	7765	103183	79633380
Electroencephalogram abnormal	56.70	30.19	21	7804	5413	79731150
Cardio-respiratory arrest	56.29	30.19	61	7764	108449	79628114
Maternal exposure during delivery	56.13	30.19	15	7810	1331	79735232
Respiratory acidosis	54.25	30.19	25	7800	11175	79725388
Muscle rigidity	53.99	30.19	30	7795	19852	79716711
Tracheal deviation	53.36	30.19	10	7815	171	79736392
Seizure	52.87	30.19	78	7747	188756	79547807
Ventricular fibrillation	52.67	30.19	35	7790	31891	79704672
Status epilepticus	52.65	30.19	32	7793	25009	79711554
Therapeutic product effect prolonged	52.30	30.19	12	7813	567	79735996
Clonus	52.01	30.19	21	7804	6819	79729744
Premature delivery	49.37	30.19	30	7795	23437	79713126
Phrenic nerve paralysis	47.04	30.19	10	7815	331	79736232
Seizure like phenomena	46.90	30.19	14	7811	1853	79734710
Nausea	46.56	30.19	18	7807	957178	78779385
Stress cardiomyopathy	45.12	30.19	22	7803	11144	79725419
Unresponsive to stimuli	45.10	30.19	40	7785	55748	79680815
Blood magnesium decreased	45.06	30.19	25	7800	16487	79720076
Premature labour	44.65	30.19	20	7805	8370	79728193
Post procedural complication	43.90	30.19	28	7797	23801	79712762
Anaphylactoid shock	43.72	30.19	11	7814	770	79735793
Fear	43.42	30.19	27	7798	21959	79714604
Metabolic acidosis	42.09	30.19	46	7779	82483	79654080
Allergy test negative	41.58	30.19	9	7816	325	79736238
Anaesthetic complication neurological	40.71	30.19	10	7815	634	79735929
Drug ineffective	40.21	30.19	210	7615	1080703	78655860
Haemodynamic instability	38.57	30.19	23	7802	17359	79719204
Symptom masked	37.44	30.19	11	7814	1379	79735184
Muscle contractions involuntary	37.27	30.19	14	7811	3751	79732812
Anhedonia	36.45	30.19	21	7804	14877	79721686
Trismus	35.51	30.19	15	7810	5452	79731111
Methaemoglobinaemia	35.28	30.19	15	7810	5542	79731021
Normal newborn	34.92	30.19	16	7809	7056	79729507
Arthralgia	34.69	30.19	7	7818	571796	79164767
Renal impairment	34.20	30.19	58	7767	157725	79578838
Airway complication of anaesthesia	34.19	30.19	8	7817	412	79736151
Headache	33.94	30.19	11	7814	653761	79082802
Hypotonia	33.79	30.19	19	7806	12851	79723712
Myoclonic epilepsy	33.66	30.19	11	7814	1959	79734604
Paralysis	33.38	30.19	19	7806	13158	79723405
Kounis syndrome	32.05	30.19	13	7812	4269	79732294
CSWS syndrome	32.03	30.19	5	7820	26	79736537
Encephalopathy	31.67	30.19	36	7789	67361	79669202
Hypercapnia	31.36	30.19	16	7809	8919	79727644
Tryptase increased	30.69	30.19	8	7817	645	79735918
Vasoplegia syndrome	30.57	30.19	12	7813	3618	79732945

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M03AB01	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Choline derivatives
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D009466	Neuromuscular Blocking Agents
MeSH PA	D009467	Neuromuscular Depolarizing Agents
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175719	Depolarizing Neuromuscular Blocker
FDA PE	N0000175733	Neuromuscular Depolarizing Blockade
CHEBI has role	CHEBI:51371	muscle relaxants
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Muscle relaxation, function	indication	11977004
General anesthesia	indication	50697003
Skeletal Muscle Relaxation for Endotracheal Intubation	indication
Ocular hypertension	contraindication	4210003	DOID:9282
Hypocalcemia	contraindication	5291005
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Glaucoma	contraindication	23986001	DOID:1686
Infectious disease	contraindication	40733004
Myxedema	contraindication	43153006	DOID:11634
Hypokalemia	contraindication	43339004
Burn injury	contraindication	48333001
Bradycardia	contraindication	48867003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Muscular dystrophy	contraindication	73297009	DOID:9884
Duchenne muscular dystrophy	contraindication	76670001	DOID:11723
Third degree burn injury	contraindication	80247002
Spinal cord injury	contraindication	90584004
Myasthenia gravis	contraindication	91637004	DOID:437
Fracture of bone	contraindication	125605004
Disorder of muscle	contraindication	129565002	DOID:423
Spasticity	contraindication	221360009
Rhabdomyolysis	contraindication	240131006
Anemia	contraindication	271737000	DOID:2355
Injury of eye region	contraindication	282752000
Deficiency of cholinesterase	contraindication	360607009
At risk for aspiration	contraindication	371736008
Primary malignant neoplasm	contraindication	372087000
Surgical procedure on eye proper	contraindication	373353005
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Malignant hyperthermia	contraindication	405501007
Cardiac arrest	contraindication	410429000	DOID:0060319
Traumatic injury	contraindication	417746004
Cardiac Decompensation	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Muscle-type nicotinic acetylcholine receptor	Ion channel	P02708 P07510 P11230 Q04844 Q07001	ACHA_HUMAN ACHG_HUMAN ACHB_HUMAN ACHE_HUMAN ACHD_HUMAN	AGONIST				CHEMBL	CHEMBL
Acetylcholinesterase	Enzyme		ACES_MOUSE		Ki	4.68		CHEMBL

External reference:

ID	Source
4017730	VUID
N0000178917	NUI
D00766	KEGG_DRUG
71-27-2	SECONDARY_CAS_RN
4017730	VANDF
4019935	VANDF
C0038627	UMLSCUI
CHEBI:45652	CHEBI
SCK	PDB_CHEM_ID
CHEMBL703	ChEMBL_ID
CHEMBL983	ChEMBL_ID
DB00202	DRUGBANK_ID
5314	PUBCHEM_CID
4004	IUPHAR_LIGAND_ID
10154	RXNORM
1940	MMSL
5517	MMSL
d00376	MMSL
001676	NDDF
005590	NDDF
372724004	SNOMEDCT_US
3822002	SNOMEDCT_US
58907007	SNOMEDCT_US
D013390	MESH_DESCRIPTOR_UI
26	INN_ID
J2R869A8YF	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9960	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	13 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9983	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	19 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9983	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	19 sections
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6970	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6970	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6970	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	29 sections
QUELICIN	Human prescription drug label	1	0409-6970	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	29 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3009	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	23 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3411	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3411	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3411	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-9053	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-9053	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-9053	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Succinylcholine Chloride	Human Prescription Drug Label	1	14445-407	INJECTION	20 mg	INTRAVENOUS	ANDA	22 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-104	INJECTION	20 mg	INTRAVENOUS	ANDA	21 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-104	INJECTION	20 mg	INTRAVENOUS	ANDA	21 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-104	INJECTION	20 mg	INTRAVENOUS	ANDA	21 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-493	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	26 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-493	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	26 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	25021-677	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	31 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	25021-677	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	31 sections
Succinylcholine Chloride	Human Prescription Drug Label	1	31722-981	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	30 sections
Succinylcholine Chloride	Human Prescription Drug Label	1	31722-981	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	30 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-371	INJECTION	200 mg	INTRAMUSCULAR	ANDA	24 sections